


NEXUS/VNA

The universal archive



HALF-YEAR REPORT

01ST JANUARY TO 30TH OF JUNE 2022

Financial Highlights for the Half-Year 2022 and 2021

	30/06/2022	30/06/2021	Change
Sales and operating result	KEUR	KEUR	(in %)
Sales	100,032	90,857	10.1
Segment revenues Healthcare Software (unconsolidated)	97,096	87,185	11.4
Segment revenues Healthcare Service (unconsolidated)	4,586	7,159	-35.9
Domestic sales	52,544	48,537	8.3
Sales in foreign countries	47,488	42,320	12.2
EBITDA	20,823	18,391	13.2
EBITA	14,766	12,329	19.8
EBIT	12,403	10,147	22.2
EBT	11,956	9,932	20.4
Consolidated net income	9,151	7,580	20.7
Cash flow from operating activities	29,666	27,070	9.6
Earnings per share (undiluted/diluted) in EUR	0.58	0.48	20.8
Ongoing development costs and depreciations			
Capitalization of software developments	1,182	1,340	-11.8
Total depreciation	8,420	8,244	2.1
Acquisition-related depreciation from purchase price allocation	2,363	2,182	8.3
Assets and equity capital			
Non-current assets	184,021	181,118 ¹⁾	1.6
Current assets	78,972	66,223 ¹⁾	19.3
Liquid assets	38,352	26,172 ¹⁾	46.5
Equity capital	156,675	142,403 ¹⁾	10.0
Share price (closing price, Xetra, in EUR)	50.00	62.80	-20.4
Employees (Half-Year average)	1,534	1,448	5.9

¹⁾ Key date 31/12/2021

As rounded figures are used in this report, it is possible that the totals and calculated percentage figures may vary slightly.

Letter to our Shareholders

Dear Shareholders,

The picture of our business is currently full of **contradictions**: On the one hand, the large government investment programs in the digitization of the healthcare system provide a unique opportunity **to significantly increase our sales and market shares in the coming years**. The hospitals in Germany and France are currently awarding large orders under the Hospital Future Act (KHZG) and SÉGUR programs, and investments in e-health applications are also increasing in other countries.

On the other hand, the **pandemic, the war, inflation and the shortage of skilled workers** are challenges that we never experienced in this combination in the past. The consequences of the pandemic with high sick leave and access restrictions for our customers make our service business much more difficult. Home office and quarantine rules also meant that we are less present at our customers than we would like to be. The Russian war of aggression in Ukraine has had a drastic economic impact and the shortage of skilled workers, which has worsened significantly in recent months, necessitates a constant reassessment of staff and location strategies.

All in all, this is a challenging starting point, which requires a high level of vigilance on the part of the entire NEXUS team.

Results

Therefore, we are all the more delighted that we can also show **a strong increase in sales and earnings in the first half of 2022** and consequently successfully continue our strong growth history once again.

In the first half year, our sales increased by approx. **10.1% to EUR 100.03 million**. Earnings before interest and income taxes (EBIT) increased by approx. **22.2% to KEUR 12,403**. With an EBITDA of approx. KEUR 20,823 and an operating cash flow of **KEUR 29,666**, we are again able to present a very strong result for the first half year. Earnings per share rose by 20.8% to EUR 0.58.

The sales figures include company acquisitions for the current year amounting to KEUR 1,123 and even **KEUR 3,169 consolidated** when the previous year's acquisitions are included. Thanks to the consolidations of the current year, EBIT increased by KEUR 123 and KEUR 104 when the previous year is included.

It should be noted that the revenues and results of DC-Systeme Informatik GmbH have been integrated in the Laboratory business area and are therefore no longer reported as acquired revenues. The special hardware sales of KEUR 1,839 in the „DRV Deutsche Rentenversicherung Bund“ project in the previous year were a one-off effect that was adjusted to calculate the organic sales comparison. Adjusted for these two effects, organic sales increased by 8.9% and organic EBIT increased by 21.2%.

Currency effects were mainly caused by the stronger Swiss franc and the weaker Polish zloty and contributed a total of KEUR 996 to sales and KEUR 157 to earnings.

Market

These are good results, especially since the state-funded digitization programs launched in the pandemic have **not yet made a contribution** to sales. The first projects from the Hospital Future Act (KHZG) and SÉGUR will be settled in the fourth quarter of 2022. Over the past six months, we have worked intensively to prepare these projects in terms of concept and sales, and we have been able to develop a very high order backlog.

In addition to the government programs, we also received **interesting new orders**: Important bids that we won and which were important successes include the Charité's decision to introduce NEXUS / E&L at three Charité sites for gastroenterology and pneumology, the orders of Maria Hilf Hospital in Mönchengladbach and the two hospitals of the Wertachklinik, Bobingen for the introduction of the NEXUS / HIS, and the University of Bonn, which opted for NEXUS / RIS. The large order from Gelderland Valley Hospital in the Netherlands for the introduction of the NEXUS / HIS and the order of the Lower Austrian State Health Agency for the introduction of the NEXUS / QM software at up to 27,000 workplaces in the state health facilities are also certainly **outstanding successes**. We are starting the second half of the year with this high order backlog, which will occupy us intensively in the coming months.

Our **Russian business** will have no significant impact on our business figures. We provide software for determining the risk of pregnancies in approx. 145 clinics. We provisionally discontinued this business in February 2022, but the contribution to sales and earnings is relatively small.

However, we will have to observe the **further effects** of the war. The same applies to the development of the pandemic as well as the energy and economic crisis. We will closely monitor their impact on public finances, inflation and interest rate markets. However, we currently see no reason to change our risk assessment from 2021 for the businesses divisions. Risk management and a description of the major risks were explained in detail in the 2021 Annual Report.

Products

We will focus strongly on our innovation projects in the second half of 2022. We are currently focusing on the **organic expansion** of our business. Hospitals are ready to invest in innovative and cost-saving solutions. That is why it is important to speed up our new developments. We are especially focusing on **"NEXUS / ADVANCED REPORTING"**. This module supports the creation of findings texts and diagnoses based on image analyses, predefined terminologies and experience (AI). As a result, findings can be produced significantly faster and in higher quality. Starting with demanding endoscopic, cardiological and radiological findings, we will use the module in all our software applications across the board and internationally in the future. We are convinced of the success of this development and speak resolutely of **a leap in efficiency and quality in clinical informatics**. We are proud that we have already received the first international orders for this module. Other very important modules are **"NEXUS / PORTAL"**, which improves the digital communication between practitioners and patients, and **"NEXUS / VNA"**, i.e., clinic-wide image and document archiving, which enables a complete view of patient records.

Acquisitions

In addition to concentrating on the organic expansion of our business, we were able to recruit **five smaller, highly specialized teams** in 2022, which strengthen our "Laboratory" business segment and our Swiss subsidiary. Since February 2022, we have held a 51% stake in oneICT AG. The company is strengthening NEXUS / Schweiz in the area of ICT services. The team of HeimSoft Solutions AG is helping us to expand our leadership in the market of Swiss institutions. We have strengthened our "Laboratory" business area by acquiring 70% of the shares in IFMS GmbH, Saarbrücken as of 31 May 2022 and an asset deal on the business operations of On-Lab GmbH, Offenburg as of 2 May 2022. Both highly specialized teams enable us to serve the laboratory and pathology market even more broadly and expand our position.



— Dr. Ingo Behrendt, Chief Executive Officer (CEO)

OUTLOOK: Positioned clearly!

The first half of the year was once again very challenging due to a variety of factors: war, pandemic, shortage of skilled workers, and inflation. All these factors challenge us and our customers in many areas. Against this background, we are therefore proud that the NEXUS team is once again in good shape. We achieved a very convincing result with growth of approx. 10% and improvement in EBIT of approx. 22%,

We have been able to **minimize the business consequences of the crises for NEXUS** until now. However, we cannot rest on our laurels. Especially with respect to costs for staff and energy, we must continuously evaluate further developments and make adjustments there if necessary. NEXUS is in a good position: We are debt-free and do not depend on critical value chains. As a result, we can focus on managing remaining risks.

The NEXUS team remains firmly committed to **positioning us clearly** as an innovative, fast-growing and profitable company in the market. The industry environment provides us with the opportunity to successfully position our product innovations, and we continue to see potential for smaller acquisitions in the upstream consolidation phase. We are therefore optimistic about the rest of the year, especially since we will have the opportunity to realize sales from the national digitization programs in the fourth quarter.

The NEXUS team is looking forward to these opportunities.




Warm regards,



Dr. Ingo Behrendt

Chief Executive Officer

Economic key figures



Interim Annual Report

REPORT ABOUT THE PROFIT, FINANCIAL AND ASSET SITUATION

NEXUS Group sales increased from KEUR 90,857 to KEUR 100,032 (+10.1%) in the first six months of the year 2022. The stable, positive sales development of NEXUS Group of recent years could be continued with that.

In the Healthcare Service Division, sales of KEUR 4,586 were achieved after KEUR 7,159 (6M-2021). In the previous year, we posted revenue of EUR 1,839,000 for hardware in this segment, which we adjusted as a one-off effect. Without this turnover, the segment would have realised a sale of KEUR 5,320 in the first half of 2021, i.e. around 13.8 % lower than in the previous year. This includes sales of KEUR 1,611 ((6M-2021): KEUR 3,455) with the Healthcare Software segment. On the other hand, sales increased from KEUR 87,185 (6M-2021) to KEUR 97,096 (+11.4%) in the Healthcare Software Division. This includes sales of KEUR 39 ((6M-2021): KEUR 32) with the Healthcare Service segment.

We respect to the regional development of sales, we were able to increase sales in Germany by 8.3% to KEUR 52,544 ((6M-2021): KEUR 48,537). In international business, we achieved sales of KEUR 47,488 in the first half-year 2022 compared to KEUR 42,320 in the previous year (+12.2%). Sales in Austria (+56.6%), the Netherlands (+22.4%) and in Switzerland (+12.1%) were very strong, while business performance in Poland (-8.3%) and France (-0.9%) decreased slightly.

Consolidated earnings before income interest and taxes (EBIT) developed very positively. They improved by 22.2% to KEUR 12,403 ((6M-2021): KEUR 10,147). IFMS GmbH, Zwicky Electronic AG, HeimSoft Solutions AG and oneICT AG as well as the transferred business operations of On-Lab GmbH consolidated for the first time, had no significant impact on the EBIT development in the first half-year. A value of KEUR 14,766 was achieved in EBITA and consequently was 19.8% over the value of previous year ((6M-2021): KEUR 12,329). EBITDA reached KEUR 20,823 in the first half-year of 2022 ((6M-2021): KEUR 18,391) and consequently was 13.2% higher than in the previous year. The non-recurring costs for the integration of the new companies in the first half-year of 2022 amounted to approx. KEUR 801.



Cash flow from operating activities amounted to KEUR 29,666 (6M-2021: KEUR 27,070) in the first half-year, which is 9.6% higher than in the previous year. This is a high value, which especially resulted from prepayments on projects and maintenance contracts.

The consolidated surplus increased by 20.7% and amounted to KEUR 9,151 for the first half-year 2022 following KEUR 7,580 (6M-2021). There is a slight decrease in the tax rate there. The undiluted result per share amounted to EUR 0.58 ((6M-2021): EUR 0.48) (diluted: EUR 0.58; (6M-2021): EUR 0.48).

Cash resources including short-term financial assets amounted to KEUR 38,352 on 30/06/2022 (31/12/2021: KEUR 26,172).

Investments in tangible and intangible assets were made in the amount of KEUR 2,740 in the first half-year 2022 ((6M-2021): KEUR 2,323). This includes KEUR 1,182 ((6M-2021): KEUR 1,340) for capitalizing software developments.

The balance sheet total increased from KEUR 247,341 to KEUR 262,993 compared to 31/12/2021 (+6.3%). Intangible assets, goodwill and balanced-out deferred taxes add up to a total of KEUR 153,948 following previously KEUR 152,312 (31/12/2021). Receivables from customers amount to KEUR 28,038 following KEUR 31,930 on 31/12/2021.



EMPLOYEES

NEXUS Group employed an average of 1,534 people in the first six months (6M-2021: 1,448 employees).

CHANGES IN OWNERSHIP INTEREST

The following changes were implemented in the ownership interest structure:

- + NEXUS Schweiz AG, a wholly owned subsidiary of Nexus AG, acquired 60% of the shares of oneICT AG, Wallisellen (Switzerland), on 09/02/2022. A put/call option contract exists for a further 40% of the shares.
- + ASTRAIA Software GmbH was renamed NEXUS / ASTRAIA GmbH on 04/03/2022.
- + NEXUS Schweiz AG acquired a further 25% of the shares of the subsidiary osoTec GmbH, Affoltern am Albis (Switzerland), on 16/03/2022 from the existing option agreement.
- + Nexus AG acquired 70% of the shares in IFMS GmbH, Institut für medizinische Software, Saarbrücken, on 18/03/2022 with closing on 31/05/2022 and the associated transfer of the shares as well as the initial consolidation on this date. A put/call option contract exists for a further 30% of the shares.
- + NEXUS Schweiz AG acquired a further 20% of the shares of the subsidiary Creativ Software AG, Widnau (Switzerland), on 18/03/2022 from the existing option agreement.

- + NEXUS / CSO GmbH was renamed NEXUS / REHA GmbH on 15/04/2022.
- + On 02/05/2022, DC-Systeme Informatik GmbH acquired the business operations of On-Lab GmbH as part of an asset deal.
- + Nexus AG acquired a further 10.94% of the shares of the subsidiary NEXUS POLSKA sp. z o.o., Poznan (Poland), on 09/05/2022 from the existing option agreement.
- + E&L medical Systems GmbH was renamed NEXUS / E&L GmbH on 11/05/2022.
- + NEXUS Schweiz AG acquired 100% of the shares of Zwicky Electronic AG, Bottighofen (Switzerland), on 31/05/2022.
- + NEXUS Schweiz AG acquired 100% of the shares of HeimSoft Solutions AG, Zollikofen (Switzerland), on 01/06/2022.

EVENTS AFTER THE BALANCE SHEET DATE

- + There were no events after the balance sheet date.

Finance Highlights Half-Year 2022

- + 20.7% increase in the consolidated surplus from KEUR 7,580 (6M-2021) to KEUR 9,151
- + 22.2% increase in Group result for earnings before interest and taxes (EBIT) from KEUR 10,147 (6M-2021) to KEUR 12,403
- + Continued very strong operational cash flow in the first half-year of KEUR 29,666
- + High net liquidity of KEUR 38,352

SALES BY REGION

	01/01/2022- 30/06/2022	01/01/2021- 30/06/2021	Change	01/04/2022- 30/06/2022	01/04/2021- 30/06/2021	Change
	KEUR	KEUR	%	KEUR	KEUR	%
Germany	52,544	48,537	8.3	26,831	25,325	5.9
Switzerland /Liechtenstein	22,084	19,695	12.1	10,335	9,852	4.9
Netherlands	12,321	10,069	22.4	6,528	5,092	28.2
Poland	3,293	3,592	-8.3	1,947	2,413	-19.3
France	3,430	3,460	-0.9	1,738	1,752	-0.8
Austria	2,420	1,545	56.6	1,212	673	80.1
Other countries	3,940	3,959	-0.5	1,942	1,810	7.3
Total	100,032	90,857	10.1	50,533	46,917	7.7

SALES BY OPERATING SEGMENTS

	Healthcare Software		Healthcare Service		Consolidation		Group	
	01/01/2022- 30/06/2022	01/01/2021- 30/06/2021	01/01/2022- 30/06/2022	01/01/2021- 30/06/2021	01/01/2022- 30/06/2022	01/01/2021- 30/06/2021	01/01/2022- 30/06/2022	01/01/2021- 30/06/2021
	KEUR							
Sales to third parties	97,057	87,153	2,975	3,704	—	—	100,032	90,857
Sales between segments	39	32	1,611	3,455	-1,650	-3,487	—	—
Segment revenues	97,096	87,185	4,586	7,159	-1,650	-3,487	100,032	90,857

Stock Market, Event and Financial Data

Investor Relations – Successful Together!

We rely on transparent, regular and timely communication in dialog with the capital market. Our goal is to build trust and work together with our investors on the success of NEXUS.

We provide our investors a wide range of opportunities to exchange ideas at conferences, road shows and one-on-one meetings.

Melanie Ilic

Investor Relations
Tel.: +49 771 22960-260
Fax: +49 771 22960-226
E-Mail: ir@nexus-ag.de



Company Profile

nexus/ag

Nexus AG develops and sells software solutions for the international healthcare market. With our core Hospital information system (NEXUS / HIS) and integrated diagnostic modules (NEXUS / DIS), we have a unique product range, which can cover almost all functional requirements of hospitals, psychiatric institutions, rehabilitation facilities and diagnostic centers within our own product families.

NEXUS employs approx. 1,650 people, is present in seven European countries with its own sites and serves customers in an additional 23 countries via certified dealers.

Thanks to continuously growing demand for NEXUS products, we have been able to build up a large customer base in recent years and regularly show increases in sales and results.

Financial calendar



Stock market prices

- + Initial listing on 03/01/2022: 71,90 EUR
- + Highest price on 04/01/2022: 73,10 EUR
- + Stock market capitalization on 30/06/2022: 790,73 Mio. EUR
- + Closing price on 30/06/2022: 50,00 EUR


Frankfurt stock exchange stock prices (1-year period)



NEXUS/VNA

The universal archive

Regardless of whether images, scans, reports or laboratory reports, NEXUS/VNA enables secure access to all patient documents. A VNA platform that displays all data relevant to a patient at one glance.



TOOLS



DATA FORMATS

- Documents
- Video and DICOM data
- Administrative data
- Structured (discrete) data
- Laboratory values
- Manufacturer-independent
- Holistic archiving platform

IMAGING

Specialist department-specific viewer for findings and image data



Compliant with the Medical Products Law

SHARE FUNCTION

Networking


Standard-compliant, external data exchange and data analysis



PROCESS FEATURE

Workflows

Routing documents as well as process automation via own workflow engine



RESULT

WOW

All data are archived manufacturer-independent in a universal archive, which enables specialist-overlapping and specific access.



Consolidated Profit and Loss

	01/01/2022- 30/06/2022	01/01/2021- 30/06/2021	01/04/2022- 30/06/2022	01/04/2021- 30/06/2021
	KEUR	KEUR	KEUR	KEUR
Revenue	100,032	90,857	50,534	46,917
Capitalized development costs	1,182	1,340	591	670
Other operating income	3,458	1,925	1,970	944
Cost of goods sold	15,845	14,408	8,154	8,096
Staff costs	59,446	54,692	29,645	27,915
Impairment Loss on Financial Assets	-	-	-12	-
Other operating expenses	8,558	6,631	4,660	3,215
EBITDA	20,823	18,391	10,648	9,305
Depreciation	8,420	8,244	4,230	4,207
EBIT	12,403	10,147	6,418	5,098
Financial income	2	17	1	89
Financial expenses	449	232	132	225
EBT	11,956	9,932	6,287	4,962
Taxes	2,805	2,352	1,529	1,202
Consolidated net income	9,151	7,580	4,758	3,760
Consolidated net income apportioned to:				
– Shareholders of the Parent Company	9,108	7,528	4,936	3,847
– Non-controlling interests	43	52	-178	-87
Consolidated earnings per share				
Weighted average (undiluted) of issued shares in circulation (in thousands)	15,770	15,748	15,766	15,748
Weighted average (diluted) of issued shares in circulation (in thousands)	15,770	15,748	15,766	15,748
Undiluted in EUR	0.58	0.48	0.32	0.25
Diluted in EUR	0.58	0.48	0.32	0.25

Consolidated Statement of Comprehensive Income

	01/01/2022- 30/06/2022	01/01/2021- 30/06/2021
	KEUR	KEUR
Consolidated net income	9,151	7,580
Other comprehensive income		
Items that will not be reclassified to profit / loss		
Remeasurement from pension plans recognised in equity	11,930	1,866
Deferred taxes on revaluation from pension plans recognised in equity	-1,933	-301
Items that may be reclassified to profit / loss		
Currency translation differences	336	-797
Deferred taxes on currency translation differences	65	-34
Other comprehensive income before taxes	12,266	1,069
Deferred taxes on other comprehensive income	-1,868	-335
Other comprehensive income after taxes	10,398	734
Consolidated income	19,549	8,314
Consolidated income apportioned to:		
– Shareholders of the Parent Company	19,493	8,259
– Non-controlling interests	56	55

Consolidated Balance Sheet

ASSETS	30/06/2022	31/12/2021
Non-current assets	KEUR	KEUR
Goodwill	107,654	102,927
Other intangible assets	44,653	46,597
Fixed assets	12,085	11,938
Right-of-use assets	17,592	16,475
Deferred tax assets	1,641	2,788
Other financial assets	396	393
Total non-current assets	184,021	181,118
Current assets		
Inventories	1,171	1,691
Trade and other receivables	28,038	31,930
Contract assets	3,659	2,234
Other non-financial assets	6,073	3,670
Other financial assets	1,679	526
Cash and cash equivalents	38,352	26,172
Total current assets	78,972	66,223
Total assets	262,993	247,341

LIABILITIES	30/06/2022	31/12/2021
Equity	KEUR	KEUR
Subscribed capital	15,815	15,815
Capital reserves	34,550	34,470
Retained earnings	101,818	95,863
Other comprehensive income	3,558	-6,827
Capital redemption reserve	-2,690	-529
Shareholders' equity attributable to parent	153,051	138,792
Non-controlling interests	3,624	3,611
Total equity	156,675	142,403
Non-current liabilities		
Pension obligations	5,249	16,295
Deferred tax liabilities	10,279	10,363
Other financial liabilities	7,352	6,211
Lease liabilities	13,252	12,072
Total non-current liabilities	36,132	44,941
Current liabilities		
Accrued liabilities	7,039	6,016
Deferred liabilities	15,360	13,399
Other non-financial liabilities	8,543	21,549
Trade payables	3,797	5,043
Contract liabilities	29,725	4,047
Other financial liabilities	1,151	5,384
Lease liabilities	4,571	4,559
Total current liabilities	70,186	59,997
Balance sheet total	262,993	247,341

Consolidated Statement of Changes in Equity

	Subscribed capital	Capital reserves	Retained earnings	Accumulated other comprehensive income
	KEUR	KEUR	KEUR	KEUR
Equity as at 01/01/2021	15,752	33,307	81,703	-10,669
Remeasurement from pension plans recognised in equity	-	-	-	1,862
Deferred taxes on revaluation from pension plans recognised in equity	-	-	-	-300
Currency translation differences	-	-	-	-797
Deferred taxes on currency translation differences	-	-	-	-34
Other comprehensive income after taxes	-	-	-	731
Consolidated net income 6M-2021	-	-	7,528	-
Consolidated income	-	-	7,528	731
Dividend payouts	-	-	-2,992	-
Dividend payouts to non-controlling interests	-	-	-	-
Issuance of treasury stock	-	-	-	-
Addition (+) and disposal (-) of non-controlling interests	-	-	-127	-
Equity as at 30/06/2021	15,752	33,307	86,112	-9,938
Equity as at 01/01/2022	15,815	34,470	95,863	-6,827
Remeasurement from pension plans recognised in equity	-	-	-	11,911
Deferred taxes on revaluation from pension plans recognised in equity	-	-	-	-1,929
Currency translation differences	-	-	-	338
Deferred taxes on currency translation differences	-	-	-	65
Other comprehensive income after taxes	-	-	-	10,385
Consolidated net income 6M-2022	-	-	9,108	-
Consolidated income	-	-	9,108	10,385
Dividend payouts	-	-	-3,153	-
Dividend payouts to non-controlling interests	-	-	-	-
Purchase of treasury stock	-	-	-	-
Access within the framework of share-based payment	-	80	-	-
Equity as at 30/06/2022	15,815	34,550	101,818	3,558

	Capital redemption reserve	Shareholders' equity attributable to parent	Non-controlling interests	Total equity capital
	KEUR	KEUR	KEUR	KEUR
Equity as at 01/01/2021	108	120,201	3,382	123,583
Remeasurement from pension plans recognised in equity	-	1,862	4	1,866
Deferred taxes on revaluation from pension plans recognised in equity	-	-300	-1	-301
Currency translation differences	-	-797	-	-797
Deferred taxes on currency translation differences	-	-34	-	-34
Other comprehensive income after taxes	-	731	3	734
Consolidated net income 6M-2021	-	7,528	52	7,580
Consolidated income	-	8,259	55	8,314
Dividend payouts	-	-2,992	-	-2,992
Dividend payouts to non-controlling interests	-	-	-44	-44
Issuance of treasury stock	66	66	-	66
Addition (+) and disposal (-) of non-controlling interests	-	-127	-	-127
Equity as at 30/06/2021	174	125,407	3,393	128,800
Equity as at 01/01/2022	-529	138,792	3,611	142,403
Remeasurement from pension plans recognised in equity	-	11,911	19	11,930
Deferred taxes on revaluation from pension plans recognised in equity	-	-1,929	-4	-1,933
Currency translation differences	-	338	-2	336
Deferred taxes on currency translation differences	-	65	-	65
Other comprehensive income after taxes	-	10,385	13	10,398
Consolidated net income 6M-2022	-	9,108	43	9,151
Consolidated income	-	19,493	56	19,549
Dividend payouts	-	-3,153	-	-3,153
Dividend payouts to non-controlling interests	-	-	-43	-43
Purchase of treasury stock	-2,161	-2,161	-	-2,161
Access within the framework of share-based payment	-	80	-	80
Equity as at 30/06/2022	-2,690	153,051	3,624	156,675

Consolidated Cash Flow Statement

	01/01/2022- 30/06/2022	01/01/2021- 30/06/2021
1. Cash flow from operating activities	KEUR	KEUR
EBIT	12,403	10,147
Depreciation (+)/amortization (-) on intangible assets and fixed assets	5,995	5,772
Depreciation (+) on rights of use leased assets	2,425	2,472
Other non-operating expenses (+)/income (-)	-1,665	372
Increase (-)/decrease (+) in inventory	632	367
Gains (-)/losses (+) on the disposal of assets and investments	-	-22
Increase (-)/decrease (+) in receivables and other assets	-1,299	-5,817
Increase (+) / decrease (-) in provisions	937	17
Increase (+)/decrease (-) in liabilities	12,507	16,067
Interest paid (-) / interest received (+)	-760	-218
Income taxes paid (-) / income tax refunds (+)	-1,509	-2,088
	29,665	27,070
2. Cash flow from investment activities		
Payments (-) for investments in intangible assets and property, plant and equipment	-2,740	-2,323
Proceeds (+) from the disposal of intangible assets and property, plant and equipment	-	23
Payments (-) for the acquisition of consolidated companies less the funds acquired	-2,951	-14,709
Payments (-) / receipts (+) from the acquisition / disposal of short-term financial assets	-	1,728
	-5,691	-15,281
3. Cash flow from financing activities		
Payments (-) for purchase of non-controlling interests for already consolidated companies	-4,472	-1,545
Payments (-) for redemption of lease liabilities	-2,380	-2,284
Payments (-) for redemption of loan liabilities	-	-721
Dividends paid (-)	-3,153	-2,992
Dividends paid to non-controlling interests (-)	-43	-44
Payments (-) for the purchase of treasury stock	-2,161	-
Proceeds (+) from the sale of treasury stock	-	66
	-12,209	-7,520
Change in cash and cash equivalents	11,765	4,270
Effect of exchange rate changes on cash and cash equivalents	415	-1,164
Cash and cash equivalents at the start of the period	26,171	26,449
Cash and cash equivalents at the end of the period	38,352	29,555
Composition of cash and cash equivalents		
Cash and bank balances	38,352	29,553
	38,352	29,553

Notes to the Consolidated Interim Financial Report

1. TRADE AND OTHER RECEIVABLES; CONTRACT ASSETS

Trade and Other Receivables

	30/06/2022	31/12/2021
	KEUR	KEUR
Gross total	32,658	37,754
Risk provisioning IFRS 9	-476	-1,097
Sales adjustment for items still to be clarified	-4,144	-4,727
Total	28,038	31,930

Long-term receivables are contained in the trade receivables with a credit term longer than one year in the amount of KEUR 0 (31/12/2021: KEUR 29).

The fair value of trade account receivables and other receivables does not differ from the book value. On 30/06/2022, trade receivables of KEUR 4,620 (31/12/2021 with a nominal value of KEUR 5,824) were impaired.

Contract assets

	30/06/2022	31/12/2021
	KEUR	KEUR
Gross total	3,709	2,256
Risk provisioning IFRS 9	-50	-22
Total	3,659	2,234

Contract assets do include items with a maturity greater than one year in the amount of KEUR 0 (previous year: KEUR 1,618).

2. LIABILITIES

	30/06/2022		31/12/2021		30/06/2021	
	short-term (< 1 year)	long-term (> 1 year)	short-term (< 1 year)	long-term (> 1 year)	short-term (< 1 year)	long-term (> 1 year)
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Accruals	15,360	—	13,399	—	10,774	—
Financial liabilities	—	—	—	—	721	—
Trade accounts payable	3,797	—	5,043	—	4,982	—
Other non-financial debts	8,543	—	11,737	—	7,178	—
- Taxes on earnings obligations	3,807	—	4,227	—	2,309	—
- Other taxes	4,736	—	7,510	—	4,869	—
Contract liabilities	29,725	—	13,859	—	26,978	—
Other financial debts	1,151	7,352	5,384	6,211	8,202	8,645
Rights of use liabilities	4,571	13,252	4,559	12,072	4,458	12,174
Total	63,147	20,604	53,981	18,283	63,293	20,819

* Specific data from previous years has been adjusted to conform to the current presentation in order to improve comparability.

Conditions of the financial liabilities listed above:

- + Average down payments on orders are offset after 12 months.
- + Liabilities from deliveries and services are not interest-bearing and normally are due within 30 days.

3. SEGMENT REPORTING

Reporting by business segment as of 30/06/	Healthcare Software		Healthcare Service		Consolidation		Group	
	2022	2021	2022	2021	2022	2021	2022	2021
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Sales with customers	97,057	87,153	2,975	3,704	—	—	100,032	90,857
- Services	74,636	66,622	2,855	3,594	—	—	77,491	70,216
- Licenses	16,517	14,132	68	66	—	—	16,585	14,198
- Deliveries	5,904	6,399	52	44	—	—	5,956	6,443
Sales between segments	39	32	1,611	3,455	-1,650	-3,487	—	—
Segment sales	97,096	87,185	4,586	7,159	-1,650	-3,487	100,032	90,857
Operating segment result	12,354	9,695	49	452	—	—	12,403	10,147
Segment assets	256,222	187,448	6,771	5,389	—	—	262,993	192,837

4. SEGMENTING ACCORDING BUSINESS DIVISIONS

The Group is split into business units according to products and services for the purpose of company management and has the following business segments required to file reports:

Healthcare Software

In the business units NEXUS Germany, NEXUS Rest of Europe and NEXUS / DIS, software solutions for the healthcare system are developed and marketed in administrative and medical areas. The economic development of these business units reacts uniformly to external influences. In addition, the offered products and services, the service creation process, the customers and the sales methods are almost identical or similar. For the reasons cited, these three business units are combined in the reportable segment Healthcare Software.

Healthcare Service

The operative segment NEXUS / CMS (Consulting & Managed Services) not allocated to the Healthcare Software reporting segment reports as an independently operating Healthcare Service segment with mandatory reporting. The companies combined under Healthcare Service are managed uniformly. Functions in the daily management of hospital IT are provided under the label NEXUS / CLOUD IT: from operations management to the support of the software applications used and user support. EDP-supported process consulting and SAP-HCM consulting, is mainly offered under the brand NEXUS / ENTERPRISE SOLUTIONS.

The balance sheet and valuation methods of both segments with mandatory reporting correspond to the same accounting methods as external reporting. Transactions between the segments are settled at customary market conditions.

5. SEASONAL INFLUENCES ON BUSINESS TRANSACTIONS

Within the context of the operative business of NEXUS Group, seasonal effects result due to the receipt of maintenance revenues in the first quarter of the business year (the revenue influences of the corresponding received payments are accrued over the business year) as well as the substantially higher demand and settlement of project accounts in the fourth quarter of the business year.

6. ACCOUNTING AND VALUATION METHOD

This interim report of the NEXUS Group of 30/06/2022 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account.

The regulations of IAS 34 were observed in the interim report of 30/06/2022. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Notes to the Group Financial Statement 2021. The same accounting and valuation methods were used in the Group Financial Statement for the fiscal year 2021.

The report has not been audited.

The Group Financial Statement 2021 and the interim report of 30/06/2022 can be seen on the homepage in the internet at www.nexus-ag.de.

List of consolidated subsidiaries		30/06/2022	31/12/2021
Full consolidation	Country	Capital share in %	
ANT-Informatik AG, Zurich ¹⁾	Switzerland	100.00	100.00
ANT-Informatik GmbH, Siegburg ²⁾	Germany	100.00	100.00
Creativ Software AG, Widnau ³⁾	Switzerland	100.00	100.00
DC-Systeme Informatik GmbH, Heiligenhaus ⁴⁾	Germany	100.00	100.00
HeimSoft Solutions AG, Zollikofen ⁵⁾	Switzerland	100.00	-
highsystem ag, Zurich ⁶⁾	Switzerland	95.00	95.00
ifa systems AG, Frechen	Germany	52.56	52.56
ifa united i-tech Inc., Fort Lauderdale ⁷⁾	USA	100.00	100.00
ifa-systems informationssysteme für augenärzte GmbH, Vienna ⁷⁾	Austria	100.00	100.00
IFMS GmbH, Saarbrücken ⁸⁾	Germany	100.00	-
Inoveon Corp., Oklahoma City ⁷⁾	USA	100.00	100.00
ITR Software GmbH, Lindenberg ⁹⁾	Germany	100.00	100.00
NEXUS / ASTRAIA GmbH, Ismaning (formerly: ASTRAIA Software GmbH) ^{4) 10)}	Germany	100.00	100.00
NEXUS / CHILI GmbH, Dossenheim	Germany	83.73	83.73
NEXUS / CLOUD IT GmbH, Donaueschingen ⁴⁾	Germany	100.00	100.00
NEXUS / DIS GmbH, Frankfurt am Main ⁴⁾	Germany	100.00	100.00
NEXUS / E&L GmbH, Nürnberg (formerly: E&L medical systems GmbH) ^{4) 11)}	Germany	100.00	100.00
NEXUS / ENTERPRISE SOLUTIONS GmbH, Donaueschingen	Germany	100.00	100.00
NEXUS / IPS GmbH, Donaueschingen ⁴⁾	Germany	100.00	100.00
NEXUS / MARABU GmbH, Berlin ⁴⁾	Germany	100.00	100.00
NEXUS / QM GmbH, Singen Hohentwiel ⁴⁾	Germany	100.00	100.00
NEXUS / REHA GmbH, Donaueschingen (formerly: NEXUS / CSO GmbH) ^{4) 12)}	Germany	100.00	100.00
Nexus Deutschland GmbH, Donaueschingen ⁴⁾	Germany	100.00	100.00
NEXUS Digitale Dokumentationssysteme Projektentwicklungsges.m.b.H., Vienna	Austria	100.00	100.00
NEXUS Nederland B.V., Nieuwegein	Netherlands	100.00	100.00
NEXUS POLSKA Sp. z o.o., Posen ¹³⁾	Poland	100.00	100.00
NEXUS Schweiz AG, Altishofen	Switzerland	100.00	100.00
NEXUS SISINF SL, Sabadell	Spain	100.00	100.00
NEXUS SWISSLAB GmbH, Berlin ⁴⁾	Germany	100.00	100.00
Nexus/France S.A.S. Grenoble	France	100.00	100.00

List of consolidated subsidiaries		30/06/2022	31/12/2021
Full consolidation	Country	Capital share in %	
oneICT AG, Wallisellen ¹⁴⁾	Switzerland	100.00	-
osoTec GmbH, Affoltern am Albis ¹⁵⁾	Switzerland	100.00	100.00
RVC Medical IT B.V., Amersfoort ¹⁶⁾	Netherlands	100.00	100.00
RVC Medical IT GmbH, Freiburg im Breisgau ¹⁶⁾	Germany	100.00	100.00
RVC Medical IT Holding B.V., Amersfoort ¹⁷⁾	Netherlands	100.00	100.00
RVC Medical IT N.V., Antwerp ¹⁶⁾	Belgium	100.00	100.00
SINAPSI Sagl, Lugano ¹⁸⁾	Switzerland	100.00	100.00
Sophrona Solutions Inc., St Paul ¹⁹⁾	USA	100.00	100.00
Zwicky Electronic AG, Bottighofen ²⁰⁾	Switzerland	100.00	-

¹⁾ The shares are held indirectly by NEXUS Schweiz AG. The stake subject to corporate law is only 63,92 %. The remaining 36,08 % of shares are governed by an option agreement.

²⁾ The shares are held indirectly by ANT-Infomatik AG.

³⁾ NEXUS Schweiz AG purchased the remaining 20 % of the shares in its subsidiary Creativ Software AG from the existing option agreement on 18/03/2022.

⁴⁾ Use of the exemption rule pursuant to Art. 264 (3) HGB.

⁵⁾ NEXUS Schweiz AG purchased 100 % of the shares in HeimSoft Solutions AG on 01/06/2022.

⁶⁾ The shares are held indirectly by NEXUS Schweiz AG. The stake subject to corporate law is only 80 %. The remaining 15 % of shares are governed by an option agreement.

⁷⁾ The shares are held indirectly by ifa systems AG.

⁸⁾ Nexus AG purchased 70 % of the shares in IFMS GmbH on 01/06/2022. The remaining 30 % of shares are governed by an option agreement.

⁹⁾ The stake subject to corporate law is only 51 %. The remaining 49 % of shares are governed by an option agreement.

¹⁰⁾ ASTRAIA Software GmbH was renamed NEXUS / ASTRAIA GmbH on 04/03/2022.

¹¹⁾ E&L medical systems GmbH was renamed NEXUS / E&L GmbH on 11/05/2022.

¹²⁾ NEXUS / CSO GmbH was renamed NEXUS / REHA GmbH on 15/04/2022.

¹³⁾ NEXUS AG purchased the remaining 10.94 % of the shares in its subsidiary NEXUS POLSKA Sp. z o.o. from the existing option agreement on 09/05/2022.

¹⁴⁾ NEXUS Schweiz AG purchased a 60 % stake in oneICT AG on 09/02/2022. A put/call option contract exists for a further 40 % of the shares.

¹⁵⁾ The stake subject to corporate law is only 80 %. The remaining 20 % of shares are governed by an option agreement. NEXUS Schweiz AG purchased an additional 25 % of the shares in its subsidiary osoTec GmbH from the existing option agreement on 16/03/2022.

¹⁶⁾ The shares are held indirectly by RVC Medical IT Holding B.V..

¹⁷⁾ The stake subject to corporate law is only 92,46 %. The remaining 7,54 % of shares are governed by an option agreement.

¹⁸⁾ The shares are held indirectly by NEXUS Schweiz AG.

¹⁹⁾ The shares are held indirectly by ifa united i-tech Inc.. The stake subject to corporate law is only 80%. The remaining 20% of shares are governed by an option agreement.

²⁰⁾ NEXUS Schweiz AG purchased 100 % of the shares in Zwicky Electronic AG on 31/05/2022.

7. CONSOLIDATION GROUP

In addition to the Nexus AG as parent company, all operatively active domestic and foreign subsidiaries are included in the Group Financial Statement, for which Nexus AG has the majority of voting rights directly or indirectly.

8. CHANCES AND RISKS REPORT

Please refer to the explanations in the Annual Report of 31/12/2021 for information about the essential chances and risks in the development of NEXUS Group. Risks and opportunities in connection with COVID 19 – especially for the development of sales and earnings – were pointed out in this half-year report. A precise assessment of the possible effects is not possible at this time.

__ Statement from the Legal Representatives

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Donaueschingen, 16/08/2022

Nexus AG

The Executive Board

Nexus AG, Irmastraße 1, 78166 Donaueschingen

Tel. +49 771 22960-0, Fax +49 771 22960-226

www.nexus-ag.de, info@nexus-ag.de